US 12,403,087 B2
Topical antiviral compositions, delivery systems, and methods of using the same
Kimberly McHale, Hillsborough, NC (US); Ryan Doxey, Raleigh, NC (US); and Nathan Stasko, Chapel Hill, NC (US)
Assigned to Ligand Pharmaceuticals Incorporated, Jupiter, FL (US)
Filed by Ligand Pharmaceuticals Incorporated, Jupiter, FL (US)
Filed on Jun. 23, 2023, as Appl. No. 18/340,177.
Application 18/340,177 is a continuation of application No. 17/329,587, filed on May 25, 2021, granted, now 11,723,858.
Application 17/329,587 is a continuation of application No. 16/840,657, filed on Apr. 6, 2020, granted, now 11,040,006, issued on Jun. 22, 2021.
Application 16/840,657 is a continuation of application No. 16/431,214, filed on Jun. 4, 2019, granted, now 10,736,839, issued on Aug. 11, 2020.
Application 16/431,214 is a continuation of application No. 15/713,185, filed on Sep. 22, 2017, granted, now 10,322,082, issued on Jun. 18, 2019.
Application 15/713,185 is a continuation in part of application No. 15/324,332, granted, now 10,322,081, issued on May 18, 2019, previously published as PCT/US2015/039908, filed on Jul. 10, 2015.
Application 15/713,185 is a continuation of application No. PCT/US2016/012668, filed on Jan. 8, 2016.
Application PCT/US2016/012668 is a continuation in part of application No. PCT/US2015/039908, filed on Jul. 10, 2015.
Claims priority of provisional application 62/139,176, filed on Mar. 27, 2015.
Claims priority of provisional application 62/023,587, filed on Jul. 11, 2014.
Prior Publication US 2023/0330008 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/675 (2006.01); A61K 33/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01)
CPC A61K 9/0014 (2013.01) [A61K 9/06 (2013.01); A61K 31/675 (2013.01); A61K 33/00 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 24 Claims
 
1. A delivery system comprising a composition comprising a nitric oxide (NO)-releasing active pharmaceutical ingredient,
wherein the NO-releasing active pharmaceutical ingredient is a NO-releasing compound comprising an NO donor selected from the group consisting of a diazeniumdiolate, nitrosothiol, nitrosamine, hydroxyl nitrosamine, hydroxyl amine and hydroxyurea and the NO-releasing active pharmaceutical ingredient is present in the composition in an amount of 0.01% to 30% by weight of the composition,
wherein the composition stores and/or releases nitric oxide in an amount of about 0.05% to about 10% by weight of the composition, wherein the delivery system releases nitric oxide in a cumulative amount of at least about 90 nmol of NO/mg of the delivery system at 4 hours after administration, as measured by real time in vitro release testing, and
wherein the delivery system is in the form of a ring, suppository, and/or sponge.